ReviewCurrent oncology reports2021

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines).

Andrea De Giglio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.